Generation and characterization of mice with a conditional null allele of the HtrA4 gene

Liu,Ju; Li,Yan; Hoh,Josephine

doi:10.3892/mmr.2015.4291

Generation and characterization of mice with a conditional null allele of the HtrA4 gene

Authors:
- Ju Liu
- Yan Li
- Josephine Hoh
View Affiliations

Affiliations: Department of Epidemiology and Public Health, Yale University, New Haven, CT 06520, USA, Children's Health Care Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: September 3, 2015 https://doi.org/10.3892/mmr.2015.4291
Pages: 6768-6774
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

High temperature requirement factor A4 (HtrA4) is a member of the HtrA family of serine peptidases involved in regulating protein‑protein interactions. Little is known regarding the function of HtrA4 in humans and in mouse models. To gain insights into the role of HtrA4 in vivo, mice were generated with a conditional null allele of HtrA4 by flanking exons 4, 5 and 6 with loxP sites. Cre‑mediated recombination, using a ubiquitously active Rosa26‑Cre line, resulted in the deletion of the floxed region in the mouse genome. Mice homozygous for the recombinant allele (HtrA4‑/‑) were viable, fertile and appeared to be normal. The HtrA4 protein was detectable in coronary vessels and in the placenta. However, the loss of HtrA4 affected neither the basic heart nor placental functions. These mice, featuring a conditional null allele of HtrA4, may provide a valuable tool to investigate the role of HtrA4 in development and pathogenesis of coronary heart disease and preeclampsia.

View Figures

View References

1	Strauch KL and Beckwith J: An Escherichia coli mutation preventing degradation of abnormal periplasmic proteins. Proc Natl Acad Sci USA. 85:1576–1580. 1988. View Article : Google Scholar : PubMed/NCBI
2	Pallen MJ and Wren BW: The HtrA family of serine proteases. Mol Microbiol. 26:209–221. 1997. View Article : Google Scholar
3	Clausen T, Southan C and Ehrmann M: The HtrA family of proteases: Implications for protein composition and cell fate. Mol Cell. 10:443–455. 2002. View Article : Google Scholar : PubMed/NCBI
4	Zurawa-Janicka D, Skorko-Glonek J and Lipinska B: HtrA proteins as targets in therapy of cancer and other diseases. Expert Opin Ther Targets. 14:665–679. 2010. View Article : Google Scholar : PubMed/NCBI
5	Vande Walle L, Lamkanfi M and Vandenabeele P: The mitochondrial serine protease HtrA2/Omi: An overview. Cell Death Differ. 15:453–460. 2008. View Article : Google Scholar : PubMed/NCBI
6	Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, et al: HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 314:989–992. 2006. View Article : Google Scholar : PubMed/NCBI
7	Grau S, Richards PJ, Kerr B, Hughes C, Caterson B, Williams AS, Junker U, Jones SA, Clausen T and Ehrmann M: The role of human HtrA1 in arthritic disease. J Biol Chem. 281:6124–6129. 2006. View Article : Google Scholar
8	Tsuchiya A, Yano M, Tocharus J, Kojima H, Fukumoto M, Kawaichi M and Oka C: Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis. Bone. 37:323–336. 2005. View Article : Google Scholar : PubMed/NCBI
9	Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH and Shridhar V: A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene. 23:1636–1644. 2004. View Article : Google Scholar : PubMed/NCBI
10	Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricalà C, Amantea A, Noonan DM, Albini A, et al: The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene. 21:6684–6688. 2002. View Article : Google Scholar : PubMed/NCBI
11	Park HJ, Seong YM, Choi JY, Kang S and Rhim H: Alzheimer's disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Neurosci Lett. 357:63–67. 2004. View Article : Google Scholar : PubMed/NCBI
12	Bakay M, Zhao P, Chen J and Hoffman EP: A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord. 12(Suppl 1): S125–S141. 2002. View Article : Google Scholar : PubMed/NCBI
13	Ross OA, Soto AI, Vilariño-Güell C, Heckman MG, Diehl NN, Hulihan MM, Aasly JO, Sando S, Gibson JM, Lynch T, et al: Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord. 14:539–543. 2008. View Article : Google Scholar : PubMed/NCBI
14	Zhu F, Jin L, Luo TP, Luo GH, Tan Y and Qin XH: Serine protease HtrA1 expression in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 9:508–512. 2010.PubMed/NCBI
15	Clausen T, Kaiser M, Huber R and Ehrmann M: HTRA proteases: Regulated proteolysis in protein quality control. Nat Rev Mol Cell Biol. 12:152–162. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ketteler R, Sun Z, Kovacs KF, He WW and Seed B: A pathway sensor for genome-wide screens of intracellular proteolytic cleavage. Genome Biol. 9:R642008. View Article : Google Scholar : PubMed/NCBI
17	Inagaki A, Nishizawa H, Ota S, Suzuki M, Inuzuka H, Miyamura H, Sekiya T, Kurahashi H and Udagawa Y: Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia. Placenta. 33:919–926. 2012. View Article : Google Scholar : PubMed/NCBI
18	Soriano P: Generalized lac Z expression with the ROSA26 Cre reporter strain. Nat Genet. 21:70–71. 1999. View Article : Google Scholar : PubMed/NCBI
19	Chien J, Campioni M, Shridhar V and Baldi A: HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets. 9:451–468. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wang LJ, Cheong ML, Lee YS, Lee MT and Chen H: High-temperature requirement protein A4 (HtrA4) suppresses the fusogenic activity of syncytin-1 and promotes trophoblast invasion. Mol Cell Biol. 32:3707–3717. 2012. View Article : Google Scholar : PubMed/NCBI
21	Hayashi T, Yoshida S, Yoshinaga A, Ohno R, Ishii N and Yamada T: HtrA2 is up-regulated in the rat testis after experimental cryptorchidism. Int J Urol. 13:157–164. 2006. View Article : Google Scholar : PubMed/NCBI
22	Liu J, Dong F and Hoh J: Loss of HtrA1-induced attenuation of TGF-β signaling in fibroblasts might not be the main mechanism of CARASIL pathogenesis. Proc Natl Acad Sci USA. 112:E16932015. View Article : Google Scholar
23	Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A, Kawata H, Koyama A, Arima K, Takahashi T, et al: Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med. 360:1729–1739. 2009. View Article : Google Scholar : PubMed/NCBI
24	Kato MV: A secreted tumor-suppressor, mac25, with activin-binding activity. Mol Med. 6:126–135. 2000.PubMed/NCBI
25	Nakamura T, Takio K, Eto Y, Shibai H, Titani K and Sugino H: Activin-binding protein from rat ovary is follistatin. Science. 247:836–838. 1990. View Article : Google Scholar : PubMed/NCBI
26	Hu SI, Carozza M, Klein M, Nantermet P, Luk D and Crowl RM: Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem. 273:34406–34412. 1998. View Article : Google Scholar : PubMed/NCBI
27	Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, Yano M, Tsuchiya A, Ueta Y, Soma A, Kanda H, et al: HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development. 131:1041–1053. 2004. View Article : Google Scholar : PubMed/NCBI